Cambridge vaccine AZD1222 is expected to be available before Christmas

Reporter : Yuning

Editor : Chang Qing

Publisher : Sound Of Hope

Ref : https://www.soundofhope.org/post/403081

Translation, editing : Gan Yung Chyan

                                 / KUCINTA SETIA

The vaccine developed by Oxford University to extinguish the virus SARS-CoV-2 has entered the stage of human testing. The initial test results show that this vaccine can stimulate immunity in subjects for nearly two months with minimal side effects. Researchers estimate that if everything goes according to the original plan, this vaccine can be launched in December 2020 and will be used by high-risk groups first.

According to a report by the Daily Mail, the research results published by The Lancet magazine show that this vaccine named AZD1222 was tested in the first phase of 1,077 human subjects at the end of May, of which 543 subjects inoculated with this vaccine, more than 500 subjects were injected with meningitis vaccine for comparison.

The test results showed that there were no obvious side effects except for some subjects experiencing headache, fatigue or muscle pain at the injection site, and 91% of subjects had immunity to SARS-CoV-2 for more than one month.

The researchers said that this vaccine stimulated enough antibodies to neutralize the invading virus in the subject, and also activated the subject's immune system, which can kill the lymphocyte T-cells that kill the invading virus. The outlook for this vaccine is very optimistic.

The test results also showed that the subject's antibody immunity climaxed four weeks after the injection of the reagent, and remained high until the test was repeated 56 days later. Since 56 days is the last test, the antibody content in the subject remains high afterwards. In a test group of 35 people, all the subjects had enough antibodies to neutralize the invading virus 28 days after the vaccine injection, preventing it from spreading in the body.

In terms of T cells, in a group of 43 subjects, the number of T cells increased significantly, and 14 days after the injection, the T cells responded most strongly to the protruding protein in the invading COVID-19, and then landed.

The researchers said that it is not yet clear whether these immune responses triggered by the vaccine in the subjects are sufficient to prevent the subjects from being infected with the virus, but this result has met their expectations, making them believe that this reagent is expected to be effective.

The report stated that the University of Cambridge plans to test the vaccine for 50,000 people in the next six weeks, including a large-scale test in the United States to ensure that the vaccine can be marketed by the end of this year.

Researchers predict that if everything goes according to plan, this vaccine may be used by high-risk people by the end of this year. They also recommend that the two vaccines be injected together because the effect is more obvious.

AstraZeneca Pharmaceuticals in Sweden has begun to produce this vaccine, and the British government has ordered 100 million doses of this vaccine.

The British government is currently collecting test vaccines around the world. The government also ordered a total of 90 million covid vaccines in Germany and France on July 20. The British government hopes that at least one of these vaccines will be able to work.

The BBC reported that tests found that an interferon protein called SNG001 developed by the British biotech company Synairgen can reduce the number of critically ill patients requiring ventilators by 79% and reduce the average length of hospitalization by 1/3 , The average hospital stay was reduced from 9 days to 6 days.

However, the BBC stated that since this result was not published in a professional journal, nor did it provide all the data of the test, it was only the initial test result provided by Synairgen for the stock market, so the BBC could not confirm its authenticity.